Written questions by Ribeiro-Addy.

For what reason the Sickle Cell day unit in Whitechapel was closed.

The same day emergency care pilot for sickle cell patients at the Royal London Hospital was commissioned locally, via the NHS North East London Integrated Care Board. The pilot finished in January 2026 as planned. The pilot was testing an alternative route for treating emergency patients with sickle cell disease who were experiencing acute pain. This was alongside the normal route of being treated through accident and emergency, which patients can still access. During the pilot, the trust has gathered internal evaluation data to monitor the impact of the pilot for patients locally, allowing them to plan for the delivery of future sickle cell services. Although NHS England did not commission this pilot, they remain committed to the reducing health inequalities faced by people living with sickle cell and will continue to work in collaboration with system partners to address these inequalities through evidence-based approach.Sickle cell disease patients still receive specialist care through the Haematology Day Unit at the Royal London Hospital, and this remains open. There has been no change for patients with regards to routine or emergency management of their condition. There are several innovations in the sickle cell service currently being implemented such as the expansion of the red cell exchange transfusion service and the delivery of novel curative gene therapies.

How many sickle cell day centres have closed in the last 5 years; and how many sickle cell day centres remain operational.

The same day emergency care pilot for sickle cell patients at the Royal London Hospital was commissioned locally, via the NHS North East London Integrated Care Board. The pilot finished in January 2026 as planned. The pilot was testing an alternative route for treating emergency patients with sickle cell disease who were experiencing acute pain. This was alongside the normal route of being treated through accident and emergency, which patients can still access. During the pilot, the trust has gathered internal evaluation data to monitor the impact of the pilot for patients locally, allowing them to plan for the delivery of future sickle cell services. Although NHS England did not commission this pilot, they remain committed to the reducing health inequalities faced by people living with sickle cell and will continue to work in collaboration with system partners to address these inequalities through evidence-based approach.Sickle cell disease patients still receive specialist care through the Haematology Day Unit at the Royal London Hospital, and this remains open. There has been no change for patients with regards to routine or emergency management of their condition. There are several innovations in the sickle cell service currently being implemented such as the expansion of the red cell exchange transfusion service and the delivery of novel curative gene therapies.

What assessment he has made of the potential impact of proposed changes to funding for non-clinical NHS departments on a) patient wait times, b) hospital running costs and c) hospital administration.

National Health Service providers are funded under the NHS payment scheme. When providing funding for services, the clinical and non-clinical elements of service provision are not distinguished, as a single overall price is provided.We have, however, been clear about the need for providers to reverse the growth in corporate costs, which since 2018/19 have risen by 40%, or £1.85 billion, excluding pay and pensions. Providers have been asked to reduce that growth in corporate costs by half.Those savings can then be reinvested in patient care, including to improve patient wait times.

What assessment he has made of the potential impact of trends in the level of the utilisation of hospice beds on NHS capacity and costs; and if he will make it his policy to allocate £100 million funding for hospices in 2025-26 and a further £100 million in April 2026.

As hospices are independent, charitable organisations, the Department and NHS England do not collect data on the level of utilisation of hospices. Whilst the majority of palliative and end of life care is provided by National Health Service staff and services, we recognise the vital part that hospices also play in providing support to people at the end of life and their loved ones, as well as alleviating pressure on NHS services.In December 2024, we announced that we were providing £100 million of capital funding for eligible adult and children’s hospices in England. This was split across two financial years, with hospices receiving £25 million to spend in 2024/25 and £75 million to spend in 2025/26.I am pleased to say that we can now confirm we are providing a further £25 million in capital funding for hospices to spend in 2025/26.Furthermore, children and young people’s hospices have received £26 million of revenue funding for 2025/26 and we are also providing £80 million of revenue funding for children and young people’s hospices over the next three financial years, from 2026/27 to 2028/29, giving them stability to plan ahead and focus on what matters most, caring for their patients.We are in a challenging fiscal position across the board. At this time, we are not in a position to offer any additional funding beyond that outlined above. However, we are trying to support the hospice sector in other ways.The Government is developing a Palliative Care and End of Life Care Modern Service Framework (MSF) for England. As part of the MSF, we will consider contracting and commissioning arrangements. We recognise that there is currently a mix of contracting models in the hospice sector. By supporting integrated care boards to commission more strategically, we can move away from grant and block contract models. In the long term, this will aid sustainability and help hospices’ ability to plan ahead.

Pursuant to the Answer of 12 November 2025 to Question 87401 on Prosthetics and Wigs: Ethnic Groups, whether he will ensure that there is guidance or a requirement for NHS Trusts to procure breast prosthesis and wigs which meet the diverse needs of their patients, beyond the availability of such products through the NHS Supply Chain frameworks.

NHS Supply Chain manages a framework agreement for the provision of external breast prosthesis and chest support garments, only which was renewed in November 2024. The framework provides the breadth of products available to meet National Health Service trusts and/or foundation trusts assessment and patient choice requirements.The product ranges on the framework include a variety of materials, types, shapes, sizes, and colours to meet diverse needs, and all suppliers have some product ranges available in more than one colour. Some products are better suited to exercise and swimming, but the provision of a prosthesis is limited to a softie, which is textile based, immediately after surgery and a silicone based prosthesis once wounds have healed.NHS trusts and foundation trusts are responsible for their own procurement activity to meet the requirements of their patients and clinicians. NHS England has a list of approved regional and national frameworks that NHS provider organisations can use, and they are encouraged to buy from a framework if it catalogues the particular product or service.The accreditation standards required to be on the list cover a range of areas, from minimum contractual terms and conditions, robust supplier appointment and value for money assessment processes, through to the sharing of commercial and commission data with NHS England.  Details and the list of accredited host organisations can be found at the following link:https://www.england.nhs.uk/long-read/system-guidance-for-the-implementation-of-framework-host-management/NHS Supply Chain is on this list and is the main supplier of goods and services into the NHS.

Pursuant to the answer of 12 November 2025 to Question 87400 on Prosthetics and Wigs: Ethnic Groups, whether he will make an assessment of the impact of limited access to suitable breast prosthesis on those patients.

NHS Supply Chain manages a framework agreement for the provision of external breast prosthesis and chest support garments, only which was renewed in November 2024. The framework provides the breadth of products available to meet National Health Service trusts and/or foundation trusts assessment and patient choice requirements.The product ranges on the framework include a variety of materials, types, shapes, sizes, and colours to meet diverse needs, and all suppliers have some product ranges available in more than one colour. Some products are better suited to exercise and swimming, but the provision of a prosthesis is limited to a softie, which is textile based, immediately after surgery and a silicone based prosthesis once wounds have healed.NHS trusts and foundation trusts are responsible for their own procurement activity to meet the requirements of their patients and clinicians. NHS England has a list of approved regional and national frameworks that NHS provider organisations can use, and they are encouraged to buy from a framework if it catalogues the particular product or service.The accreditation standards required to be on the list cover a range of areas, from minimum contractual terms and conditions, robust supplier appointment and value for money assessment processes, through to the sharing of commercial and commission data with NHS England.  Details and the list of accredited host organisations can be found at the following link:https://www.england.nhs.uk/long-read/system-guidance-for-the-implementation-of-framework-host-management/NHS Supply Chain is on this list and is the main supplier of goods and services into the NHS.

What estimate his Department has made of the number of nurses and other healthcare professionals currently exposed to hazardous medicinal products.

I refer the Hon. Member to the answer I gave to the Hon. Member for St Ives on 5 November 2025 to Question 84136.

For what reason 'Latin American' is not listed as an ethnicity option on blood donation forms.

NHS Blood and Transplant (NHSBT) is responsible for blood donation in England. NHSBT does not plan to add 'Latin American' to blood donation forms at this time. The Office for National Statistics (ONS) includes a list of ethnic groups that should be used when defining an individual’s background, and the term Latin America(n) is not used. Further information on the list of ethnic groups that should be used when defining an individual’s background is available at the following link:https://www.ons.gov.uk/methodology/classificationsandstandards/measuringequality/ethnicgroupnationalidentityandreligionThe heritage of a donor from the Latin American region can be described within mixed white, black, and other groupings. The NHS Digital site also refers to the ONS definitions, and is available at the following link:https://digital.nhs.uk/data-and-information/data-collections-and-data-sets/data-sets/mental-health-services-data-set/submit-data/data-quality-of-protected-characteristics-and-other-vulnerable-groups/ethnicityNHSBT uses several initiatives to increase blood donations and in turn improve blood stocks, and this includes marketing and communications campaigns. All activity is planned using data and insights about diverse audiences, including those from ethnic minorities. Central to all decision making is the ability to reach and connect with people from ethnic minority backgrounds. NHSBT consults with a specialist media agency to ensure they are using culturally appropriate and audience specific channels to reach mixed heritage and ethnic minority populations.

Whether he has discussions with NHS Blood and Transplant on the potential merits of including Latin American as a monitored ethnicity at the Brixton donation centre.

NHS Blood and Transplant (NHSBT) is responsible for blood donation in England. NHSBT does not plan to add 'Latin American' to blood donation forms at this time. The Office for National Statistics (ONS) includes a list of ethnic groups that should be used when defining an individual’s background, and the term Latin America(n) is not used. Further information on the list of ethnic groups that should be used when defining an individual’s background is available at the following link:https://www.ons.gov.uk/methodology/classificationsandstandards/measuringequality/ethnicgroupnationalidentityandreligionThe heritage of a donor from the Latin American region can be described within mixed white, black, and other groupings. The NHS Digital site also refers to the ONS definitions, and is available at the following link:https://digital.nhs.uk/data-and-information/data-collections-and-data-sets/data-sets/mental-health-services-data-set/submit-data/data-quality-of-protected-characteristics-and-other-vulnerable-groups/ethnicityNHSBT uses several initiatives to increase blood donations and in turn improve blood stocks, and this includes marketing and communications campaigns. All activity is planned using data and insights about diverse audiences, including those from ethnic minorities. Central to all decision making is the ability to reach and connect with people from ethnic minority backgrounds. NHSBT consults with a specialist media agency to ensure they are using culturally appropriate and audience specific channels to reach mixed heritage and ethnic minority populations.

What steps he is taking to raise awareness of sickle cell disease amongst the Latin American and Latinx community.

The Government is committed to improving the lives of those living with rare diseases such as sickle cell disease. Increasing awareness of rare diseases in healthcare professionals is one of the four priorities of the UK Rare Diseases Framework. We published the annual England action plan in February 2025, where we report on the steps we have taken to advance this priority.In England, there are approximately 17,000 people living with sickle cell disease, an inherited blood disorder with approximately 250 new cases a year. It is the fastest growing genetic condition in the country. It is generally more common in people of black African and black Caribbean heritage, 77% of patients, however, we recognise that the condition is not unique to this community and NHS England remains committed to delivering quality improvement to all patients living with sickle cell.Our national Can You Tell its Sickle Cell campaign launched in 2022, to boost public awareness of sickle cell disease, including in the Latin American and Latinx community, and help staff better understand the condition, crises, and how to care for patients during their greatest hour of need. Co-developed with NHS England’s patient advisory group, clinical experts, and the Sickle Cell Society, the campaign included staff resources as well as hand-held patient cards distributed via haemoglobinopathy coordinating centres. The campaign was relaunched as part of Sickle Cell Awareness Month in 2025, and an information toolkit remains available on the national Campaign Resource Centre.

What steps his Department is taking to increase diagnosis of sickle cell amongst patients of Latin American descent.

The Government is committed to improving the lives of those living with rare diseases such as sickle cell disease. Helping patients get a final diagnosis faster is one of the four priorities of the UK Rare Diseases Framework. We published the annual England action plan in February 2025, where we report on the steps we have taken to advance this priority.In England, there are around 17,000 people living with sickle cell disease, an inherited blood disorder with around 250 new cases a year. It is the fastest growing genetic condition in the country. It is generally more common in people of Black African and Black Caribbean heritage (77% of patients) however, we recognise that the condition is not unique to this community and NHS England remain committed to delivering quality improvement to all patients living with sickle cell.All pregnant women in England are offered a blood test to find out if they carry a gene for thalassaemia. Those at high risk of being a sickle cell carrier are offered a test for sickle cell. As part of the National Health Service Antenatal Sickle Cell and Thalassaemia (SCT) Screening Programme, the Family Origin Questionnaire (FOQ) is mandatory for all booking blood requests. By recording accurate family origin details, the FOQ enables midwives to identify women at higher risk. For example, women with Latin American ancestry extending back two generations are considered high risk and are offered screening accordingly.

What steps his Department is taking to increase blood donations among Latin American people in (a) Lambeth and (b) the rest of the UK.

NHS Blood and Transplant (NHSBT) is responsible for blood donation in England. NHSBT does not plan to add 'Latin American' to blood donation forms at this time. The Office for National Statistics (ONS) includes a list of ethnic groups that should be used when defining an individual’s background, and the term Latin America(n) is not used. Further information on the list of ethnic groups that should be used when defining an individual’s background is available at the following link:https://www.ons.gov.uk/methodology/classificationsandstandards/measuringequality/ethnicgroupnationalidentityandreligionThe heritage of a donor from the Latin American region can be described within mixed white, black, and other groupings. The NHS Digital site also refers to the ONS definitions, and is available at the following link:https://digital.nhs.uk/data-and-information/data-collections-and-data-sets/data-sets/mental-health-services-data-set/submit-data/data-quality-of-protected-characteristics-and-other-vulnerable-groups/ethnicityNHSBT uses several initiatives to increase blood donations and in turn improve blood stocks, and this includes marketing and communications campaigns. All activity is planned using data and insights about diverse audiences, including those from ethnic minorities. Central to all decision making is the ability to reach and connect with people from ethnic minority backgrounds. NHSBT consults with a specialist media agency to ensure they are using culturally appropriate and audience specific channels to reach mixed heritage and ethnic minority populations.

What assessment he has made of the potential merits of supporting a formal bilateral exchange of medical expertise between Cuba and the United Kingdom to promote health equity.

In our ever more interconnected world, international cooperation is fundamental to driving medical breakthroughs and saving lives. By sharing knowledge, resources, and expertise, international collaborations can overcome limitations faced by individual nations and achieve breakthroughs that benefit patients all over the world.The Government remains steadfast in its commitment to international collaboration on health and highly values the bilateral relationship between the United Kingdom and Cuba. The Government has a longstanding policy of engagement with Cuba, including positive collaboration in areas of mutual interest.

Whether he has made a recent assessment of the potential merits of collaboration between UK and Cuban research institutions on (a) public health and (b) genetic medicine.

In our ever more interconnected world, international research cooperation is fundamental to driving medical breakthroughs and saving lives. By sharing knowledge, resources, and expertise, international collaborations can overcome limitations faced by individual nations and achieve breakthroughs that benefit patients all over the world.Whilst no assessment has been undertaken on the specific merits of research collaboration with Cuba, through the Department funded National Institute for Health and Care Research, the Department works internationally to fund, support, and enable high impact research to address national and global health challenges.

What assessment he has made of the potential merits of international cooperation in healthcare.

In our ever more interconnected world, international cooperation is fundamental to driving medical breakthroughs and saving lives. Health challenges such as pandemics, antimicrobial resistance and climate-related impacts do not respect borders. By sharing knowledge, resources, and expertise, international cooperation can overcome limitations faced by individual nations and achieve breakthroughs that benefit patients all over the world, including the United Kingdom.The Government is committed to collaborating with our international partners and continues to engage with global health institutions, including the World Health Organization. These efforts help build resilient health systems worldwide, reduce preventable deaths and safeguard against shared threats, while supporting UK prosperity through trade and investment in health and life sciences.

Which blood donation centres have begun a trial of the Post Donation Testing for advanced Hb assessments.

NHS Blood and Transplant (NHSBT) is responsible for blood donation in England.  NHSBT’s post donation testing feasibility study will assess if an analyser-based blood count, including a haemoglobin (Hb) assessment, can be used to assess a whole blood donor’s ability to have a blood collection taken safely without the need for a Hb measurement at subsequent donation appointments. If the donor’s Hb is above specific thresholds, it will determine the need for testing at their next visit, or for a deferral period based on the Hb being too low to donate. This will start NHSBT’s ability to personalise the deferral period of donors with low Hb.This study started collecting baseline data in the London Middlesex mobile team and will roll out to the Manchester Norfolk House and Nottingham Donor Centres. These teams have been targeted to assess if testing is possible under current mobile and donor centre processes, rather than targeting specific donor groups or demographics.

What assessment his Department has made of the potential impact of the enhanced pre-donation testing process pilot on reducing the number of deferrals for low Hb levels.

NHS Blood and Transplant (NHSBT) is responsible for blood donation in England. NHSBT tests donors’ haemoglobin (Hb) to ensure they are at sufficient levels to safely donate.NHSBT has recently changed its testing to include the first line finger prick and blood drop test using copper sulphate that estimates donors’ Hb to be above the threshold for donation. If this test is failed, second line testing with venous HemoCue, a more accurate quantitative test, is carried out. If passed, a donor can donate. If failed, a donor is deferred to ensure they can replenish low iron stores to allow their Hb to improve back to safe donation thresholds.Earlier in 2025, the peak of low Hb deferrals was greater than 12%. With the rollout of venous HemoCue across the country, this has fallen to 4.5% of donors attending per week and has remained below 5% since 15 September 2025, resulting in improved collections.

What demographic data his Department considered when choosing blood donation centres to pilot the post donation testing for advanced Hb assessment.

NHS Blood and Transplant (NHSBT) is responsible for blood donation in England.  NHSBT’s post donation testing feasibility study will assess if an analyser-based blood count, including a haemoglobin (Hb) assessment, can be used to assess a whole blood donor’s ability to have a blood collection taken safely without the need for a Hb measurement at subsequent donation appointments. If the donor’s Hb is above specific thresholds, it will determine the need for testing at their next visit, or for a deferral period based on the Hb being too low to donate. This will start NHSBT’s ability to personalise the deferral period of donors with low Hb.This study started collecting baseline data in the London Middlesex mobile team and will roll out to the Manchester Norfolk House and Nottingham Donor Centres. These teams have been targeted to assess if testing is possible under current mobile and donor centre processes, rather than targeting specific donor groups or demographics.

With reference to Breast Cancer Awareness Month, what steps he is taking in November 2025 to promote inclusive (a) wig and (b) prosthetic services.

The Department and the National Health Service in England recognise that there are particular challenges for specific groups of people and for breast cancer care, particularly concerning the promotion of inclusive wigs and prosthetic services.For wigs and accessories, NHS Supply Chain has conducted extensive engagement nationally to fully understand the provision and supply and is working closely with industry groups to support access to the wigs framework, to provide a wider range of products for NHS providers to access. Appropriateness for the wearer has been one of the fundamental focus areas of consideration in this work.Decisions about the funding and provision of health services, including prosthetic services, are the responsibility of local integrated care boards. NHS England funded audits into primary and metastatic breast cancer to help identify and reduce inequalities and variations in care. Using routine data collected on patients diagnosed with breast cancer in an NHS setting, the audits bring together information to look at what is being done well, where it is being done well, and what needs to be done better. Findings were published in September 2025, and the NHS is acting on the findings.

What discussions he has had with NHS England to ensure the procurement of suitable (a) prosthetics and (b) wigs suitable for ethnic minority patients meets diverse patient needs.

The current NHS Supply Chain Wigs Framework Agreement was awarded to 42 suppliers and provides a range of wigs, both real and synthetic, and headwear products to provide alternative choices to patients, as well as maintenance, styling, alteration, and repair services.Whilst there is availability of Afro Caribbean wigs through the currently awarded suppliers, NHS Supply Chain is aware that due to the regionality of suppliers and the nature of them being predominantly micro and small to medium enterprises in many instances, patient choice and access across the United Kingdom can be subject to regional variation.NHS Supply Chain acknowledges that there is a need to develop the framework offering to support an increase in accessibility to patients for Afro Caribbean products and services, and NHS Supply Chain is preparing to introduce enhanced specifications and a specific category for Afro Caribbean for the successor framework agreement due to launch on 1 February 2027.NHS Supply Chain’s new Prosthetics, Components and Associated products Framework Agreement is due to launch on 24 November 2025, to replace the current Artificial Limbs framework. The new framework will offer over 95,000 products delivered by 12 suppliers to provide clinical choice to meet patient need. Ensuring that a patient has a prosthetic limb which blends with their actual skin tone is part of the routine standard of care. NHS Supply Chain works closely with the leading national charities and has not had any issues raised concerning accessing appropriate skin tone.